Skip to Main content Skip to Navigation
Journal articles

Bone demineralization is improved by ivacaftor in patients with cystic fibrosis carrying the p.Gly551Asp mutation

Abstract : Low bone mineral density (BMD) is a common problem in adults with cystic fibrosis (CF), the etiology of which is multifactorial. In this study, we provide the first evidence that ivacaftor improves BMD in CF patients carrying the p.Gly551Asp mutation. Consistently, in vitro experiments with TNF-α-stimulated primary F508del-CFTR osteoblasts demonstrated that correction of p.Phe508del-CFTR markedly decreased RANKL protein production, a major factor of bone resorption. These clinical and fundamental observations suggest that rescue of mutated CFTR protein improves bone remodeling and support the link between CFTR and bone cell physiology. These findings represent a step forward in the development of potential new therapies for CF-related bone disease.
Complete list of metadata

https://hal.univ-reims.fr/hal-03475342
Contributor : Marius Colin Connect in order to contact the contributor
Submitted on : Friday, December 10, 2021 - 6:01:30 PM
Last modification on : Monday, December 13, 2021 - 11:59:14 AM

Links full text

Identifiers

Collections

Citation

Isabelle Sermet-Gaudelus, Martial Delion, Isabelle Durieu, Jacky Jacquot, Dominique Hubert. Bone demineralization is improved by ivacaftor in patients with cystic fibrosis carrying the p.Gly551Asp mutation. Journal of Cystic Fibrosis, Elsevier, 2016, 15, pp.e67 - e69. ⟨10.1016/j.jcf.2016.09.003⟩. ⟨hal-03475342⟩

Share

Metrics

Les métriques sont temporairement indisponibles